MRKR will likely need to prove efficacy, either with overall survival or a surrogate endpoint (response rate or progression free survival). FDA will likely require a randomized trial, but if they can show enough of a correlation of response with immune markers and improvement on SOC considering toxicity, maybe not. Maybe we'll get some guidance here tomorrow.
News 
Market Data 
Discover 
